Literature DB >> 10757465

Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration.

I Kohno1, H Ijiri, M Takusagawa, D F Yin, S Sano, T Ishihara, T Sawanobori, S Komori, K Tamura.   

Abstract

The purpose of the study was to identify differences in the patterns of efficacy and duration of effects of imidapril administered at different times of the day (morning versus evening) in dipper and nondipper hypertensive patients. Twenty patients with untreated hypertension were classified into two groups: dippers (n = 9) and nondippers (n = 11). Imidapril (10 mg) was given at 07:00 or 18:00 for 4 weeks in a crossover fashion. Blood pressure (BP) and heart rate (HR) were monitored before and after morning and evening treatment every 30 min for 48h by ambulatory BP monitoring (ABPM). In dipper hypertension, the mean 48h BP was reduced with both doses. The decrease in the diurnal BP was stronger when the drug was administered in the evening than morning, but without significant difference. In nondipper hypertension, the systolic BP decreased at night with both doses, but the extent of the nocturnal reduction in systolic BP was greater after morning therapy. There were no significant differences in the decrease in BP during the day or night between the morning and evening administrations. When imidapril was administered in the morning, its serum concentration reached a maximum at 16:00, and when the drug was administered in the evening, it reached a maximum at 6:00. In dipper hypertension, the time taken for the blood concentration of imidapril to reach a maximum changed depending on its time of administration, and the time when the maximum antihypertensive effect of the drug appeared was different. In nondipper hypertension, decreases in the BP were confirmed at night regardless of the time of administration; this might be caused by angiotensin converting enzyme (ACE) inhibitors effectively blocking the BP from increasing by activating the parasympathetic nervous system. Therefore, when assessing the effectiveness of antihypertensive agents, factors such as the various patterns of BP before therapy and administration time must be considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757465     DOI: 10.1081/cbi-100101044

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  10 in total

1.  Imidapril: will fewer adverse events translate into better long-term outcomes?

Authors:  Tom Richart; Jan A Staessen; Willem H Birkenhäger
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 3.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

4.  Influence of the Circadian System on Disease Severity.

Authors:  Mikhail Litinski; Frank Ajl Scheer; Steven A Shea
Journal:  Sleep Med Clin       Date:  2009-06-01

Review 5.  Role of Chrononutrition in the Antihypertensive Effects of Natural Bioactive Compounds.

Authors:  Néstor Ibarz-Blanch; Diego Morales; Enrique Calvo; Laura Ros-Medina; Begoña Muguerza; Francisca Isabel Bravo; Manuel Suárez
Journal:  Nutrients       Date:  2022-05-04       Impact factor: 6.706

6.  Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats.

Authors:  Xiao-Mei Huang; Jing-Ping Yuan; Xing-Ruo Zeng; Cai-Xia Peng; Qi-Hui Mei; Wen-Li Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

Review 7.  Nocturnal hypertension: will control of nighttime blood pressure prevent progression of diabetic renal disease?

Authors:  K M Moorthi; Donn Hogan; Empar Lurbe; Josep Redon; Daniel Batlle
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

8.  Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension.

Authors:  Nikant Kumar Sabharwal; Jonathan Swinburn; Avijit Lahiri; Roxy Senior
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 9.  Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.

Authors:  Dean M Robinson; Monique P Curran; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Optimal timing for antihypertensive dosing: focus on valsartan.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.